Marex Group MRX
$58.73 −$2.69 (-4.38%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $58.79 +0.10%
Open$59.70
Prev close$61.42
Day range$55.10 – $59.70
Volume2.02M
Market cap$4.22B
P/E (TTM)9.9
Dividend yield1.06%
Earnings
Average move on report day±5.8%last 12 reports
Closed higher6 of 1250% of the time
Best reaction+18.7%
Worst reaction-7.6%
Stock move on the day after each report
| Quarter | Report date | Timing | Implied move | Actual move | Versus implied |
|---|---|---|---|---|---|
| 2026/Q3 | 5 Nov 2026 | Pre Market | ±8.8% | -7.65% | Within range |
| 2026/Q2 | 12 Aug 2026 | Pre Market | ±6.5% | +18.69% | Bigger than priced |
| 2026/Q1 | 6 May 2026 | Pre Market | ±8.3% | -5.90% | Within range |
| 2025/Q4 | 3 Mar 2026 | Pre Market | ±8.0% | -5.41% | Within range |
| 2025/Q3 | 6 Nov 2025 | Pre Market | ±10.8% | +4.67% | Within range |
| 2025/Q2 | 13 Aug 2025 | Pre Market | ±10.4% | +3.31% | Within range |
| 2025/Q1 | 15 May 2025 | Pre Market | ±6.3% | -3.41% | Within range |
| 2024/Q4 | 6 Mar 2025 | Pre Market | ±13.8% | +0.11% | Within range |
| 2024/Q3 | 7 Nov 2024 | Pre Market | ±22.0% | +1.35% | Within range |
| 2024/Q2 | 14 Aug 2024 | Pre Market | ±15.6% | +15.42% | Within range |
| 2023/Q4 | 16 May 2024 | Pre Market | – | -1.81% | – |
| 2024/Q1 | 16 May 2024 | Pre Market | – | -1.81% | – |
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Where the revenue comes from
Quarter 2026/Q3
By business line
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$743.20M+53.4% YoY
Operating profit$172.30M+82.1% YoY
Net profit$130.30M+78.0% YoY
Diluted EPS$1.45+57.6% YoY
Revenue, last 8 quarters
Net profit, last 8 quarters
Profitability & balance sheet
Gross margin47.0%
Operating margin33.1%
Net margin9.9%
Return on equity29.8%
Return on assets1.2%
Return on invested capital9.6%
Current ratio1.08
Liabilities / assets95.7%
Cash & investments$8.28B
Total debt$13.21B
Net cash (debt)-$4.94B
No comments yet — be the first to weigh in on MRX.
Sign in to join the discussion.